The Consistent Testing Terminology Working Group is composed of more than 40 patient advocacy organizations from solid tumors and hematologic malignancies, professional societies, pharma, biotech, diagnostics companies, and testing laboratories committed to clarifying and promoting consistent use of common terms for biomarker and germline genetic testing.
Background
Research shows that despite widespread acceptance of the importance of testing, actual testing rates lag far behind best-practice recommendations for both biomarker testing for somatic (acquired) mutations and other biomarkers, and for germline genetic testing for identifying germline (inherited) mutations (also known as variants).
Analysis by the Consistent Testing Terminology Working Group indicates that varied testing terms are an obstacle to patient communication with providers about testing for their specific cancer type. The pan-cancer working group identified at least 33 terms related to biomarker, genetic, and genomic testing for cancer being used in patient education today.
This varied terminology is one patient-identified reason for confusion about testing, which impedes effective communication with providers and understanding about what testing means for their care.
To best serve the needs of cancer patients, it is time to harmonize language, simplify communications, and clearly explain the goals of testing. Recommended terms identified include the following:
- “Biomarker testing” to discuss tests that identify characteristics, targetable findings, or other test results originating from malignant tissue or blood
- “Genetic testing for an inherited mutation” and “genetic testing for inherited cancer risk” for tests to identify germline mutations (also known as variants in the genetics community).
The Consistent Testing Terminology Working Group has published a white paper with industry-wide recommendations for precision medicine testing terms to be utilized in patient education and communication.
For more information on the Consistent Testing Terms Working Group, please contact Nikki Martin, Director, Precision Medicine Initiatives, LUNGevity Foundation, at nmartin@lungevity.org.
A unified voice will help the medical community and patients achieve common understanding about the benefits of testing. Join a movement to promote consistent use of common terms for biomarker and germline genetic testing and work together to achieve better communication between patients and providers about testing needs.
Download our materials here:
Healthcare Provider Information Card
ASCO Annual Meeting 2020 Abstract
Oncology Nursing Society Annual Congress 2021 Abstract
JCO Precision Oncology Manuscript 2021
Use Cases
At the Consistent Testing Terminology Use Cases Workshop on March 11, 2021, use cases for cancer terminology in several cancer types were presented. Below are the reports from the workshop.
Related Resources
Participating Organizations
With thanks to WS Collaborative for drafting the Working Group White Paper
